Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Uriry Incontinence - Overview
Uriry Incontinence - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Uriry Incontinence - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Uriry Incontinence - Companies Involved in Therapeutics Development
Cook MyoSite Inc
Crystec Ltd
Exopharm Ltd
FemmePharma Global Healthcare Inc
Innovacell Biotechnologie AG
Ixaltis
Johnson & Johnson
MUVON Therapeutics AG
Ningbo Xijian Pharmaceutical Technology Co Ltd
Outpost Medicine Ltd
Pfizer Inc
Profem GmbH
Revance Therapeutics Inc
RION Health Inc
Sanio AB
Sinsin Pharmaceutical Co Ltd
Taiho Pharmaceutical Co Ltd
Versameb AG
Uriry Incontinence - Drug Profiles
Biologic for Stress Uriry Incontinence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Stress Uriry Incontinence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Uriry Incontinence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Uriry Stress Incontinence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cevaris - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EG-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICES-13 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
iltamiocel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
litoxetine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides for Stress Uriry Incontinence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
obotulinumtoxi biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OP-352 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxybutynin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxybutynin chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prof-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize 5-HT2C for Uriry Incontinence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate kV7 for Epilepsy, Pain and Uriry Incontinence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAS-303 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tolterodine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trospium chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Uriry Incontinence - Dormant Projects
Uriry Incontinence - Discontinued Products
Uriry Incontinence - Product Development Milestones
Featured News & Press Releases
Dec 17, 2020: FDA grants RMAT desigtion for Cook MyoSite’s investigatiol autologous Muscle Derived Cells for Uriry Sphincter Repair
Jan 11, 2018: Sleep quality improves with help of incontinence drug
Jul 18, 2016: BioLife Solutions Products Embedded in Cook MyoSite Phase 3 Cell Therapy Clinical Trial for Stress Uriry Incontinence
Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg
Mar 15, 2012: Innovacell To Present Phase IIb Trial Results Of ICES13 At MedTech Investing Europe Conference
Dec 05, 2011: Pfizer’s Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients
Nov 08, 2011: Pfizer Announces Positive Top-Line Primary Endpoint Results Of Toviaz In Overactive Bladder Including Nocturl Uriry Urgency
Aug 30, 2011: Innovacell passes a further milestone
Feb 22, 2011: Innovacell makes further progress on product development
Jun 15, 2010: Innovacell Enrolls First Patient In Phase IIb Study Of Urocell For Treatment Of Uriry Incontinence
Oct 31, 2008: Fesoterodine Approved in the U.S
Sep 15, 2003: FemmePharma Receives U.S. Ind Approval for its New Therapeutic Option for Female Uriry Incontinence
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Urinary Incontinence, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021


List of Tables


Number of Products under Development for Urinary Incontinence, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Urinary Incontinence - Pipeline by Cook MyoSite Inc, 2021
Urinary Incontinence - Pipeline by Crystec Ltd, 2021
Urinary Incontinence - Pipeline by Exopharm Ltd, 2021
Urinary Incontinence - Pipeline by FemmePharma Global Healthcare Inc, 2021
Urinary Incontinence - Pipeline by Innovacell Biotechnologie AG, 2021
Urinary Incontinence - Pipeline by Ixaltis, 2021
Urinary Incontinence - Pipeline by Johnson & Johnson, 2021
Urinary Incontinence - Pipeline by MUVON Therapeutics AG, 2021
Urinary Incontinence - Pipeline by Ningbo Xijian Pharmaceutical Technology Co Ltd, 2021
Urinary Incontinence - Pipeline by Outpost Medicine Ltd, 2021
Urinary Incontinence - Pipeline by Pfizer Inc, 2021
Urinary Incontinence - Pipeline by Profem GmbH, 2021
Urinary Incontinence - Pipeline by Revance Therapeutics Inc, 2021
Urinary Incontinence - Pipeline by RION Health Inc, 2021
Urinary Incontinence - Pipeline by Saniona AB, 2021
Urinary Incontinence - Pipeline by Sinsin Pharmaceutical Co Ltd, 2021
Urinary Incontinence - Pipeline by Taiho Pharmaceutical Co Ltd, 2021
Urinary Incontinence - Pipeline by Versameb AG, 2021
Urinary Incontinence - Dormant Projects, 2021
Urinary Incontinence - Dormant Projects, 2021 (Contd..1)
Urinary Incontinence - Dormant Projects, 2021 (Contd..2)
Urinary Incontinence - Discontinued Products, 2021